 |
 |
 |
 |
 |
 |
 |
|
|
Advances in the Treatment of Chronic Myelogenous LeukemiaA presentation from the NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida, on March 16, 2007 Presenter Joseph O. Moore, MD Faculty Disclosure Statement Dr. Moore has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has received payment for serving as a speaker for Amgen Inc., Genentech, Inc., and Novartis Pharmaceuticals Corporation. Dr. Moore has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product. Program Overview This presentation will explore the latest advances in the management of patients with chronic myelogenous leukemia. Primary conventional dose therapy, second-line therapy, and patient selection for transplant will be outlined. Educational Objective Following this activity, participants should be able to discuss how advances in treatments will improve outcomes for patients with chronic myelogenous leukemia. Intended Audience This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objective and faculty disclosure statement prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 24, 2008. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. NCCN designates this educational activity for a maximum of 1.5 AMA PRA Category Nurses This activity is approved for 1.5 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: May 24, 2007 Commercial Support Distribution supported by an educational grant from Bristol-Myers Squibb Company
|
|
NCCN 1st Annual Forum: Innovative Diagnostics & Therapeutics in Cancer Care™ |
|
|
